Back to search results

RECMAP Study: Surgery for Recurrent Glioblastoma

This study, called RECMAP, is looking at different ways to remove recurrent glioblastoma (a type of brain tumor) that is located in or near important brain areas. Doctors want to understand if using "mapping" techniques during surgery helps. You might receive awake mapping (where you are awake during surgery and doctors test your brain function), asleep mapping (where you are asleep and doctors use electrical signals to test your brain), or surgery without mapping. The study is open to adults aged 18 to 90 who have recurrent glioblastoma. Success in this study will be measured by how much of the tumor is removed and if there are any new neurological problems six weeks after surgery. The current recruitment status is unclear.

Study design
This is an international, multi-center observational study that will include 225 participants. You would be assigned to one of three groups: awake mapping, asleep mapping, or surgery without mapping.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Your neurological health will be checked at six weeks after surgery.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06273176

The RECMAP-study: Resection With or Without Intraoperative Mapping for Recurrent Glioblastoma

Recruiting
Not specifiedUp to 90Observational
Erasmus Medical Center
~225 participants
Updated 2024-02-22 on ClinicalTrials.gov
What's tested:Awake mapping under local anesthesiaAsleep mapping under general anesthesiaResection under general anesthesia without mapping

At a glance

Recruiting sites
6 of 8 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Residual volume
Measured over Within 72 hours postoperatively
+1 more outcome measured

Conditions

Glioblastoma, IDH-wildtype
Glioblastoma
Glioblastoma Multiforme of Brain
Astrocytoma, Malignant
Brain Neoplasms
Brain Neoplasms, Adult, Malignant
Brain Neoplasms, Adult
Recurrent Adult Brain Tumor
Recurrent Glioblastoma

Explore related trials

Glioblastoma

Where it's being run

8 sites across 7 states
Germany2
California1
Massachusetts1
Belgium1
South Holland1
Netherlands1
Switzerland1

Study leadership

  • Jasper Gerritsen, MD PhD · PRINCIPAL_INVESTIGATOR · Erasmus Medical Center

Who to contact

Jasper Gerritsen, MD PhD
[email protected]
+31107036130
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

What this trial measures

  • Residual volumeWithin 72 hours postoperatively

    Residual tumor volume of the contrast-enhancing and non-contrast enhancing part, as assessed by a neuroradiologist on postoperative MRI scan (T1 with contrast and FLAIR sequences) using manual or semi-automatic volumetric analyses (Brainlab Elements iPlan CMF Segmentation, Brainlab AG, Munich, Germany; or similar software)

  • Neurological morbidity at 6 weeks6 weeks postoperatively

    NIHSS deterioration of 1 point or more at 6 weeks after surgery